Subscribe now
Cystic fibrosis drug halts lung damage in young children

Cystic fibrosis drug halts lung damage in young children

9 June 2017

Orkambi targets the most common mutation for cystic fibrosis, but is not available in the UK on the NHS. Now a trial has shown promising effects in children

Sign up to our weekly newsletter

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers.

Sign up
Piano Exit Overlay Banner Mobile Piano Exit Overlay Banner Desktop